Renata PLC has received the highest surveillance credit rating from Alpha Credit Rating PLC, reflecting the company’s strong financial position and stable outlook, according to a regulatory disclosure through the Dhaka Stock Exchange (DSE) published on Tuesday.
The rating agency assigned Renata “AAA” for the long term and “ST-1” for the short term, based on the company’s audited financial statements for the year ended 30 June 2025, unaudited third-quarter financial statements for July 2025-March 2026 and qualitative information available up to 14 September 2026.
Renata’s financial indicators improved during the first nine months of fiscal year 2025-26.
Its consolidated earnings per share increased to Tk20.39 during July 2025-March 2026, compared with Tk15.95 in the same period a year earlier.
Consolidated net operating cash flow per share rose to Tk22.40 from Tk21.76, while net asset value per share stood at Tk320.02 on 31 March 2026, compared with Tk305.49 on 30 June 2025.
Renata shares rose 1.08 per cent to close at Tk449.70 on the DSE on Tuesday.
The company’s history is linked to Pfizer’s Bangladesh operations. Pfizer exited Bangladesh in 1991, transferring ownership of its operations to local shareholders and management led by the late Syed Humayun Kabir.
The company was renamed Renata on 1 September 1993.
A 51 per cent majority stake of the newly formed company was vested with SAJIDA Foundation, a non-profit organisation founded by Kabir’s family.
Today, Renata operates 14 factories and exports to 69 countries, according to company information. Its portfolio includes 610 locally marketed products, 65 products approved in regulated markets and 100 bioequivalent products.
